Recent News

• 03.11.2025 - Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
• 03.11.2025 - Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
• 03.05.2025 - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
• 03.04.2025 - Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
• 03.03.2025 - Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
• 02.27.2025 - Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
• 02.26.2025 - David Hoang
• 02.25.2025 - Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
• 02.25.2025 - Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
• 02.21.2025 - Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Recent Filings

• 03.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities